Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ERYTHROPOIETIN
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Epoetin Alfa is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia-associated with Renal Insufficiency, Chronic.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 08, 2024
Lead Product(s) : ERYTHROPOIETIN
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palbociclib
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Palbociclib is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 26, 2024
Lead Product(s) : Palbociclib
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pomalidomide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Pilot Bioequivalence Study of Pomalidomide
Details : Pomalidomide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
September 28, 2023
Lead Product(s) : Pomalidomide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dorzolamide Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dorzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Glaucoma, Open-Angle.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 12, 2023
Lead Product(s) : Dorzolamide Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : L-Arginine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Megalabs USA Announces Launch of Two New Products in North American Market: Abintra and Glutapak R
Details : Abintra features a unique combination of arginine, glutamine, high-quality protein, and antioxidant vitamins and minerals in a quick-dissolving powder. The formula works to promote tissue synthesis and wound healing from within.
Product Name : Abintra
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
August 24, 2022
Lead Product(s) : L-Arginine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Filgrastim
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biosimilarity Study of Subcutaneous Filgrastim in Healthy Volunteers
Details : Filgrastim is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 12, 2021
Lead Product(s) : Filgrastim
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ERYTHROPOIETIN
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biosimilarity Study of Intravenous Recombinant Human Erythropoietin in Healthy Volunteers
Details : Erythropoietin is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 08, 2021
Lead Product(s) : ERYTHROPOIETIN
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biosimilarity Study of Subcutaneous Pegfilgrastim in Healthy Volunteers
Details : Pegfilgastim Amgen (Pegfilgrastim) is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neutropenia.
Product Name : Pegfilgastim Amgen
Product Type : Protein
Upfront Cash : Inapplicable
May 05, 2021
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bepotastine
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bepotastine Besilate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Conjunctivitis, Allergic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 01, 2021
Lead Product(s) : Bepotastine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Difluprednate
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Difluprednate is a Steroid drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cataract.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
November 17, 2020
Lead Product(s) : Difluprednate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable